Broad-spectrum vaccine against avian reovirus
A broad-spectrum vaccine against avian Reovirus is disclosed, which is effective in reducing the infection of avian Reovirus in an avian target. The vaccine comprises antigenic material derived from avian Reovirus of two genotype groups: 1 and 4, as defined herein. This vaccine is effective against all avian Reoviruses, homologous or heterologous to the vaccine, including recent virulent break-through strains.
1. A vaccine for reducing infection by avian Reovirus, the vaccine comprising an avian Reovirus antigenic material that is derived from avian Reoviruses from more than a single genotype group, and a pharmaceutically acceptable carrier, wherein the avian Reovirus antigenic material consists of antigenic material derived from a replicative form of an avian Reovirus from genotype group 1 and from a replicative form of an avian Reovirus from genotype group 4;
wherein the avian Reovirus antigenic material comprises inactivated avian Reovirus;
wherein the avian Reovirus from genotype group 1 comprises genetic information encoding a sigmaC protein comprising an amino acid sequence that has at least 85% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1; and
wherein the avian Reovirus from genotype group 4 comprises genetic information encoding a sigmaC protein comprising an amino acid sequence that has at least 85% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 4.
2. The vaccine of claim 1 , wherein the antigenic material derived from avian Reovirus from genotype group 1, is derived from avian Reovirus from genotype subgroup 1B; wherein the avian Reovirus from genotype group 1B comprises genetic information encoding a sigmaC protein comprising an amino acid sequence that has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1.
3. The vaccine of claim 1 , wherein the vaccine comprises an adjuvant.
4. The vaccine of claim 1 , wherein the vaccine comprises additional antigenic material that is derived from a micro-organism pathogenic to an avian, but not from an avian Reovirus.
5. The vaccine of claim 1 , wherein the step of inactivating both the avian Reovirus from genotype group 1 and the avian Reovirus from genotype group 4 is performed by an inactivation method selected from the group consisting of heat, radiation, formalin, beta-propiolactone, binary ethyleneimine, and beta-ethanolamine.
6. The vaccine of claim 5 , wherein the vaccine comprises additional antigenic material that is derived from a micro-organism pathogenic to an avian, but not from an avian Reovirus.
7. A method for the preparation of the vaccine of claim 1 , comprising the step of inactivating both the avian Reovirus from genotype group 1 and the avian Reovirus from genotype group 4 by a method selected from the group consisting of heat, radiation, formalin, beta-propiolactone, binary ethyleneimine, and beta-ethanolamine.
8. A method for the preparation of the vaccine of claim 1 , comprising the step of admixing the avian Reovirus antigenic material with an adjuvant.
9. A method for reducing infection by avian Reovirus in an avian, comprising administering the vaccine of claim 1 to the avian.